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Deficiency of subunit 6 of the conserved oligomeric Golgi (COG6) complex causes a new combined N- and O-
glycosylation deficiency of the congenital disorders of glycosylation, designated as CDG-IIL (COG6-CDG).
The index patient presented with a severe neurologic disease characterized by vitamin K deficiency, vomit-
ing, intractable focal seizures, intracranial bleedings and fatal outcome in early infancy. Analysis of oligosac-
charides from serum transferrin by HPLC and mass spectrometry revealed the loss of galactose and sialic
acid residues, whereas import and transfer of these sugar residues into Golgi-enriched vesicles or onto pro-
teins, respectively, were normal to slightly reduced. Western blot examinations combined with gel filtration
chromatography studies in patient-derived skin fibroblasts showed a severely reduced expression of the
mentioned subunit and the occurrence of COG complex fragments at the expense of the integral COG com-
plex. Sequencing of COG6-cDNA and COG6 gene resulted in a homozygous mutation (c.G1646T), leading to
amino acid exchange p.G549V in the COG6 protein. Retroviral complementation of the patients’ fibroblasts
with the wild-type COG6-cDNA led to normalization of the COG complex-depending retrograde protein trans-
port after Brefeldin A treatment, demonstrated by immunofluorescence analysis.
INTRODUCTION
‘Protein glycosylation’ describes the co-translational linkage
and modification of oligosaccharide moieties on newly syn-
thesized proteins. This complex metabolic process, which
has been found in nearly all forms of life from bacteria to
man, comprises one of the most widespread and variable
forms of protein modifications. Owing to their structural varia-
bility, glycans are carriers of a code that is much more
complex compared with nucleic acids and proteins. Glyco-
proteins play an important role in many biological processes
such as growth, differentiation, organ development, signal
transduction and immunologic defence, but are also involved
in pathologic processes like tumour progression (1,2). The
N- and O-glycosylation machinery is addicted to an interaction
of a bulk of proteins located in the cytosol, endoplasmic reti-
culum and the Golgi apparatus. Inborn errors in the glycosyla-
tion process in man are termed ‘congenital disorders of
glycosylation’ (CDG). They comprise a rapidly expanding
group of autosomal recessive inherited metabolic diseases,
presenting mostly with a multisystemic phenotype combined
with severe neurological impairment. In recent years, not
only defects in distinct glycosyltransferases, glycosidases or
nucleotide-sugar transporters have been identified, but also
deficiencies in the supply of products or in the maintenance
of a correct pH value, all necessary for the proper proceeding
of protein glycosylation, have been described (3–5). Further-
more, several defects in different subunits of the conserved
oligomeric Golgi (COG) complex have been identified (3).
The COG complex is a hetero-octameric protein complex
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(6–9) in the cytosol which is associated with the Golgi appar-
atus and is required for proper sorting and glycosylation of
Golgi-resident enzymes and secreted proteins. Thereby, it is
involved in the retrograde transport by COPI vesicles and
assumes a role as tethering factor for initial interactions of ves-
icles with the target membrane (9–11). Recent studies on the
COG complex structure in CDG patients let assume a subunit
interaction of COG2–COG4 and COG5–COG7 which form
lobes A and B, respectively, that are connected by COG1
and COG8 (6,9). Dysfunction of the COG complex leads to
a generalized hypoglycosylation in the cells ending up in a
severe clinical phenotype of the affected patients. Since
2004 deficiencies in subunits COG7 (12), COG1 (13), COG8
(14,15), COG4 (7) and COG5 (8) of the hetero-octameric
COG complex have been shown to lead to its malfunction
and subsequently to hypoglycosylation of glycoproteins and
therefore to CDG. Here, we present a new type of the CDG
by identification of the molecular defect in a patient with
deficiency of subunit 6 of the COG complex.
RESULTS
Case report
The index patient was the fourth child of healthy non-
consanguineous parents of Turkish origin. The family
history included two other children that died in the perinatal
period (one shortly after delivery and the other at 5 weeks
of age) with signs of an increased bleeding tendency. Preg-
nancy and delivery of the female patient were uncomplicated
and at term. The patient suffered from intractable focal sei-
zures, vomiting and loss of consciousness due to intracranial
bleedings. Biochemical investigations revealed a normal
level for albumin and mildly elevated values for lactate, aspar-
tate aminotransferase and creatine kinase. Metabolic investi-
gations revealed cholestasis and subsequent vitamin K
deficiency, explaining in part her intracranial bleedings. The
patient died due to brain oedema at 5 weeks of age. Since
the clinical phenotype of the patient was suspect for a CDG
syndrome, initial CDG diagnosis was established by isoelec-
tric focusing (IEF) of the patient’s serum transferrin.
Analyses of serum transferrin, a-1-antitrypsin
and apolipoprotein CIII
Diagnosis of CDG was performed by IEF and western blotting
of serum transferrin. The IEF pattern from the CDG-IIL patient
showed the presence of transferrin molecules with four, three,
two, one or no sialic acid residues (Fig. 1A), typical for
CDG-type II deficiencies. The partial loss of sugar residues of
N-glycans in CDG-IIL was demonstrated by a smear in
western blotting of serum transferrin (Fig. 1B) in contrast to a
control or a CDG-Ia patient, who showed defined additional
bands with faster mobility due to the complete loss of either
one or two glycan chains, typical for CDG-I deficiencies. To
confirm CDG in the patient, IEF of an alternative glycoprotein,
plasma a-1-antitrypsin, was performed. Human plasma
a-1-antitrypsin is normally glycosylated at amino acid residues
46, 83 and 247. Owing to the combinations of tri- and
di-antennary-complex-type oligosaccharides and shortened
isoforms of the protein, a pattern of seven bands in the IEF
analysis of a-1-antitrypsin in healthy controls (Fig. 1C, lane
1) is detectable. For CDG, it has been shown that additional
bands with a cathodal shift appear, the number and the size of
which depend on the corresponding type of CDG (Fig. 1C,
lanes 2 and 3). To further investigate, if the patient’s defect
also has an impact on the biosynthesis of core 1 mucin type
O-glycans, IEF of the corresponding marker protein apolipo-
protein CIII (ApoCIII) derived from sera of the patient and a
control was performed. This method allows the quantitative
determination of the three ApoCIII isoforms (ApoCIII0 – 2),
either with two sialic acid residues in 2,3 and 2,6 orientation
(ApoCIII2), with one sialic acid residue in 2,3 or 2,6 orientation
(ApoCIII1) or with no sialic acid residue (ApoCIII0). In the case
of the patient, an increased ApoCIII0 pattern was detected. This
difference in charge could be induced by a hypoglycosylation of
the glycan or a mutation in the backbone of the protein. To find
out, treatment of the patient’s and a control serum with a
2,3-sialidase and an unspecific cutting sialidase was accom-
plished. Sialidase treatment with the 2,3-sialidase revealed dis-
appearance of the fully sialylated ApoCIII2 form in the case of
the control and the patient. Where in the control, the ratio of
ApoCIII1 to ApoCIII0 was balanced, the patient showed
minor ApoCIII1. Incubation with the unspecific cutting siali-
dase led to the emergence of ApoCIII0 by deprivation of
ApoCIII1 and ApoCIII2 forms in control and the patient.
These results indicated a combined N- and O-glycosylation
deficiency in the patient.
Lectin staining with peanut agglutinin
Staining of control and patient’s fibroblasts with biotinylated
peanut agglutinin (PNA) revealed enhanced binding of the
lectin to the patient cells (data not shown). Since PNA
binds specifically to galactose-b-(1-3)-N-acetylgalactosamine
O-glycans, our result pointed to an O-glycosylation defect in
the case of the patient by indicating loss of terminal sialic
acid residues that prevents binding of PNA in the case of
the control.
Analysis of transferrin-linked N-glycans
To further investigate the transferrin-linked oligosaccharides of
the patient, transferrin was purified from control and patient’s
serum. Oligosaccharides were released with peptide-N-
glycosidase F and reductively aminated with the fluorophore
2-AB. Fractionation by HPLC showed that the main glycan
peak of the control co-eluted with a 2-AB-GlcNAc2Man3-
GlcNAc2Gal2Neu(N)Ac2 standard oligosaccharide at 49 min
(Fig. 2). In the case of the patient beyond this full-length
complex type N-glycan, several other oligosaccharides eluted
earlier (peaks at 29, 34, 39, 41 and 44 min; Fig. 2) than those
from control transferrin. This suggested that oligosaccharides
of the patient were smaller in size. Matrix-assisted laser deso-
rption/ionization–time of flight (TOF) analysis revealed, for
the major oligosaccharide from control and the patient’s
transferrin (peak at 49 min), a mass of 2343.81 Da, which
corresponds to 2-AB-GlcNAc2Man3GlcNAc2Gal2Neu(N)Ac2.
Other isolated oligosaccharides from the patient’s transferrin
revealed masses of 1437.32 Da (29 min), 1599.35 Da
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(34 min), 1761.15 Da (39 min), 1890.74 Da (41 min),
2052.75 Da (44 min) and 2343.81 Da (49 min). The loss of
two sialic acid residues and two galactose residues accounts
for the difference between 2343.81 and 1437.32 Da. The mass
of 1599.35 Da from the second oligosaccharide corresponds
to a structure with no sialic acid residue and only one galactose
residue. By loss of both sialic acid residues, a mass of
1761.15 Da would be expected. The oligosaccharide that
eluted at 41 min showed a mass of 1890.74 Da, indicating the
loss of one sialic acid residue and one galactose residue. The
fifth oligosaccharide with a mass of 2052.75 Da corresponds
to 2-AB-GlcNAc2Man3GlcNAc2Gal2Neu(N)Ac1. However,
also full-length N-linked oligosaccharides were detected. Our
results demonstrate that the N-linked oligosaccharides on the
patient’s transferrin have a complete or partial loss of galactose
and neuraminic acid residues.
Determination of UDP-galactose and CMP-NANA import
and measurement of galactose and sialic acid
residues transfer
Since our findings on transferrin-linked N-glycans mentioned
above could be explained by a deficiency of the import of UDP-
galactose into the Golgi or by a reduced transfer of galactose
residues to the glycoprotein, we determined the import of UDP-
galactose and the activity of b-1,4-galactosyltransferase in
control and patient-derived fibroblasts. Normal values for the
UDP-galactose import (98%+ 6) in combination with a slightly
decreased activity of b-1,4-galactosyltransferase (76%+5)
were detected for the patient in comparison to the control.
Besides, the import of CMP-NANA (70%+ 11) and the trans-
fer of sialic acid residues (58%+ 4) were decreased (Fig. 3).
Western blotting of the COG complex subunits
Since combined N- and O-glycosylation diseases have been
described in recent years for different defective subunits of
the COG complex, analyses of the expression levels of
COG1, COG4, COG5, COG6 and COG7 were performed
from the patient fibroblasts and normalized against the
expression of control fibroblasts. Equal amounts of protein
were used for the assays, as has been proved by b-actin stain-
ing. In contrast to COG1 (97%+ 5) and COG4 subunits
(100%+ 2), reduced signals of protein were detected for
COG5 (55%+ 7), COG6 (21%+ 8) and COG7 (62%+ 4)
in the case of the patient (Fig. 4A).
Northern blotting
To investigate, if the reduced amount of COG6 detected for the
patient in western blotting was due to a decreased translation or
successive degradation processes of theCOG6-mRNA or due to
Figure 1. (A) Serum samples from a control (lane 1), a CDG-Ia reference patient (lane 3) and the patient (lane 2) were investigated by IEF, followed by in gel
immunodetection of transferrin. Asialo, disialo and tetrasialo indicate transferrin forms carrying either 0, 2 or 4 sialic acid residues. (B) Shown are serum samples
from a control, a CDG-Ia reference patient and the patient analysed by SDS–PAGE, followed by western blotting and immunodetection of transferrin. 0, 1 and 2
indicate transferrin forms carrying 0, 1 or 2 N-glycans. (C) IEF pattern of a-1-antitrypsin. Sera from a control (lane 1), the patient (lane 2) and a CDG-Ia patient
(lane 3) were analysed by IEF. The normal pattern (lane 1) reveals seven bands. In abnormal patterns (lanes 2–3), the position of the first additional abnormal
cathodal band is indicated by an ‘arrow’. This band and all bands below are abnormal and indicate a glycosylation deficiency. (D) Analysis of core-1 mucin-type
O-linked glycans derived from ApoCIII. Serum-derived ApoCIII from a control (lanes 1–3) and the CDG-IIx patient (lane 4–6) was investigated by IEF fol-
lowed by antibody staining with a polyclonal rabbit-a-human ApoCIII antibody. ApoCIII2, ApoCIII1 and ApoCIII0 indicate the variability in the amount of sialic
acid residues linked to ApoCIII.
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a reduced expression, we performed northern blot analysis for
COG6 and b-actin. In the case of the patient, a reduced signal
for COG6 to 16%+ 4 was identified in comparison to the
control (Fig. 5), indicating that the decreased amount of
COG6 protein was provoked by the instability of the patient’s
COG6-mRNA and not by degradation of the mutated protein.
Hybridization with a probe specific for b-actin showed that
equal amounts of the control and the patient’s total RNA were
used for the test. Since western and northern blot analyses
both hint at a deficiency of COG6 or of one of the other subunits
in the respective COG complex lobe in the case of the patient,
further investigations were performed by mutational analyses
on RNA and DNA levels.
Genetic analysis
In the case of the patient, sequencing analyses of the cDNAs
for COG5, COG7 and COG8 were negative. Sequencing
analysis of the COG6-cDNA revealed in the case of the
patient a homozygous mutation (c.G1646T), leading to
Figure 2. HPLC and mass spectrometric analysis of transferrin-linked oligosaccharides. Transferrin was purified from the serum of a control and the patient.
Oligosaccharides were released by PNGase F digestion and subsequently analysed by HPLC (A patient, B control, C standard A2-2AB, D standard NGA2-
2AB). The peak fractions were further investigated by mass spectrometry. The symbols over the HPLC peaks indicate the detected oligosaccharides.
Symbols: squares, N-acetylglucosamine; grey circles, mannose; white circles, galactose; diamonds, neuraminic acid.
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Figure 3. UDP-[6-3H]galactose and CMP-[14C]NANA import into microsomes, activity of b1,4GalT1 and transfer of sialic acid onto glycoproteins of the patient
were measured and normalized to controls. Shown are data of three unrelated experiments.
Figure 4. (A) Expression of COG1, COG4, COG5, COG6 and COG7 in control and patient-derived fibroblasts was analysed by western blot. The relative signal
intensity of the respective subunit is shown as midpoint+ standard deviation (n ¼ 4) and referred to b-actin and the signal intensity of the control. (B) Gel
filtration chromatography of the COG complex. Cell lysates of fibroblasts of a control and the patient were separated by gel filtrations and analysed by
western blot with an antibody against COG4. Specified above are weights of protein standards thyroglobulin (669 kDa), ferritin (440 kDa) and aldolase
(159 kDa) plus the void volume.
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amino acid exchange p.G549V in the COG6 protein. Sequence
analysis of genomic DNA confirmed the mutational status of
the patient. In 100 control alleles, this mutation has not been
found (data not shown).
Gel filtration chromatography
To further investigate a potential impact of mutation p.G549V
on the constitution of the COG complex, cell lysates of
control and patient-derived fibroblasts were separated by gel fil-
tration chromatography, fractionated and subsequently ana-
lysed by western blot with an antibody against COG4. In the
case of the control, signals for the COG4 antibody were
mainly detected in fractions 15–20, corresponding to a mass
of 800 kDa, which would match the entire COG complex.
Additional signals were observed from fraction 25 to fraction
34 that became weaker with time. Strong signals in fractions
26 and 27 (upper band) were due to unspecific binding of the
antibody. In the case of the patient fibroblasts, signals were
detected throughout fractions 15–34 when incubated with the
COG4 antibody. In contrast to the control, the patient showed
more signals in fractions of smaller masses (Fig. 4B).
Complementation of COG6 deficiency
in CDG-IIL fibroblasts
In order to confirm the deficiency of COG6 as cause for the
glycosylation defect of our patient, we expressed the wild-type
COG6-cDNA in patient’s fibroblasts, utilizing retroviral gene
transfer. As a control, we investigated whether the retroviral
vector alone affects the functionality of the COG complex in
the patient-derived fibroblasts by retrograde protein transport
studies after Brefeldin A (BFA) treatment. BFA is widely
used to investigate the function of the Golgi apparatus and
the mechanisms regulating membrane trafficking in different
cell types.
By reversible interaction with the GDP/GTP-exchange
factor, BFA inhibits the activation of ADP-ribosylation
factor 1, and thereby interfering with elementary procedures
in the Golgi. Moreover, BFA inhibits the formation of COPI
vesicles on the Golgi apparatus, necessary for the anterograde
protein transport. Since the retrograde transport of proteins is
not affected by BFA treatment, incubation with BFA leads to
a rapid relocation of Golgi proteins into the endoplasmic
reticulum and subsequently to the disorganization of Golgi
compartments (16). As in cases of different COG deficiencies,
a significant delay in the breakdown of Golgi compartments
was noticed after BFA treatment, fibroblasts of a control and
our patient were incubated with BFA for different periods
(0–15 min) and analysed for their Golgi structures by immu-
nofluorescence studies with the Golgi marker GM130
(Fig. 6A–P) after proving that GM130 and COG4 co-localize
(data not shown). Quantification of control and patient’s fibro-
blasts was performed by analysing the ER staining pattern of
300 cells at different time points, respectively (Table 1). Non-
transduced control (Fig. 6A) and patient-derived fibroblasts
(Fig. 6E) as well as mock-transduced (Fig. 6I) and wild-type
COG6-transduced fibroblasts (Fig. 6M) of the patient
showed the localization of GM130 in all cisterns of the
Golgi apparatus at time point 0 min. In the case of the
control, degradation of the Golgi compartments was com-
pleted after 5 min incubation with BFA (Fig. 6B), where in
the case of the non-transduced (Fig. 6H) and mock-transduced
(Fig. 6L) fibroblasts of the patient, the same effect was
not visible before 15 min. After retroviral transduction of
patient-derived fibroblasts with wild-type COG6-cDNA, a
5-min incubation with BFA was sufficient for a nearly com-
plete redistribution of Golgi proteins and therefore comparable
to the non-transduced control (Fig. 6N).
DISCUSSION
In a patient who presented clinically with a multi-organic phe-
notype characterized by intractable focal seizures, vomiting
and loss of consciousness due to intracranial bleedings and
death in early infancy, we identified the deficiency of COG6
complex as a molecular cause for her disease.
Initial diagnostics for the glycosylation state of the patient’s
serum transferrin led to a characteristic CDG-II pattern. The
result was confirmed by IEF of the alternative marker
protein a-1-antitrypsin as well as by western blot analysis of
serum transferrin. Investigation of ApoCIII by IEF further
showed that also core 1 mucin-type O-glycans were affected
in the case of the patient, which accordingly led to an
enhanced staining pattern with lectin PNA. The data clearly
indicated a generalized defect in protein N- and O-
glycosylation. Since mass spectrometric investigations of the
patient’s transferrin bound N-glycans additionally revealed a
decrease in galactosylation and sialylation with all forms
from agalacto- (2-AB-GlcNAc2Man3GlcNAc2) to disialotrans-
ferrin (2-AB-GlcNAc2Man3GlcNAc2Gal2Neu(N)Ac2) com-
bined with the reduced activities of UDP-galactose and
CMP-NANA transporters as well as of b1,4GalT1 and
ST3GalTI glycosyltransferases, our data indicated comparabil-
ity in essential biochemical hallmarks known for the COG
complex diseases (6). To date, five defects in different sub-
units of the COG complex have been associated with CDG:
COG7 (12), COG1 (13), COG8 (14,15), COG4 (7) and
COG5 (8). The clinical picture of the COG defects ranges
from mildly (in the case of COG5) to severely affected with
death in early infancy (in the case of COG7 and COG6).
Nevertheless, due to the small amount of COG patients ident-
ified so far, the informative value is still limited. In general,
these patients suffer from growth retardation, failure to
Figure 5. Northern blot analysis for COG6. Total RNA was isolated from a
control and the patient and hybridized with a COG6-specific probe. Sub-
sequently, hybridization with a probe specific for b-actin was performed to
normalize the data.
3628 Human Molecular Genetics, 2010, Vol. 19, No. 18
thrive, hypotonia, microcephaly and cerebral atrophy, features
which are also known from other glycosylation deficiencies of
CDG-I and CDG-II.
Besides the biochemical characteristics mentioned above,
COG patients show instability of their affected COG
complex subunit(s). Hence, we analysed the steady-state
levels of the COG proteins of our patient by western blotting
and found clearly reduced amounts of the patient’s COG6
(minus 78%), COG5 (minus 44%) and COG7 (minus
38%) in comparison to the control, assuming an affection
of its COG complex lobe B. This is consistent with recent
findings in other COG patients, where mutations in one of
the COG subunits caused protein instability which was
always accompanied by reduced expression of at least one
other subunit of the respective lobe. Sequencing analyses
of COG5- to COG8-cDNAs revealed a homozygous
mutation (c.G1646T) in the COG6-cDNA of the patient
that caused amino acid exchange p.G549V. In contrast to
other COG patients, this mutation did not lead to reduced
amounts of COG6 by protein instability or degradation,
rather instability of the patient’s COG6-mRNA occurred,
as has been demonstrated by northern blot analysis. By gel
filtration chromatography combined with western blotting
for the detection of subunit COG4, we investigated the
effect of the reduced COG6 level on the patient’s COG
complex structure (Fig. 4B). Main signals were detected in
fractions 15–20 in the case of the control, indicating the
presence of the entire COG complex with a size of
800 kDa. Further diminishing signals with masses
between protein standards thyroglobulin (669 kDa) and aldo-
lase (158 kDa) were observed from fraction 25 on, which
could be explained by the existence of COG subcomplexes
(e.g. COG1 to COG4 plus COG8 with a mass of
460 kDa or COG5 to COG8 with a mass of 340 kDa),
since similar effects were also observed in different COG-
deficient mammalian cell lines (17). In the case of the
patient, signals indicating the full COG complex were seen
in fractions 15–20, leading to the assumption that the
mutated COG6 subunit allows for the assembly of the com-
plete COG complex. Nevertheless, in contrast to the control,
more signals in fractions 21–34 in the patient-derived fibro-
blasts with masses smaller than 700 kDa were detected,
which might be ascribed to the accumulations of COG sub-
complexes. As also signals in fractions 32–34 were
observed, there is incidence for the existence of subunit
COG4 with another subunit of lobe A or with COG1 as
Figure 6. BFA assay. Fibroblasts of a control (non-transduced, A–D) and the patient (non-transduced, E–H; mock-transduced, I–L; wild-type COG6 trans-
duced, M–P) were incubated for different periods (0–15 min) with BFA. Cells were fixed and analysed by immunofluorescence for localization of Golgi
marker GM130 (green). The cell nucleus (blue) was stained with DAPI. Bar: 10 mm.
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well as COG4 protein on its own, suggesting a complete
breakdown of the patient’s COG complex in part. If this
was due to the decrease in the steady-state level of COG6
protein in combination with down-regulations of its partners
COG5 and COG7, which might result in a lower association
of all subunits with the Golgi compartments or due to a direct
impact of mutation p.G549V on the patient’s COG complex
structure itself, remains to be solved. However, glycine 549
seems to play an important role in COG6 function, since it
is a highly conserved amino acid residue in COG6 proteins
from yeast to man. To find out if functionality of the
patient’s COG complex is affected, BFA treatment was per-
formed. As has been demonstrated for deficiencies of COG7
(18), COG8 (14,15), COG4 (7) and COG5 (8), treatment of
the respective patient cells with BFA led to a prolonged dis-
integration of the patients Golgi compartments. In the case of
our patient, BFA treatment of the fibroblasts led to a 3-fold
time delay in retrograde transport of Golgi-resident proteins
in comparison to the control, evidencing a malfunction of the
patient’s COG complex. After retroviral transduction of the
wild-type COG6-cDNA into the patient’s cells, functionality
of its COG complex could be reassembled to a control-like
rate, whereas transduction with the empty vector (mock)
led to no effect, proving that the depletion of subunit
COG6 was disease-causing in our patient.
Recent experiments from yeast presumed that the deletion
of SEC37, the corresponding subunit to human COG6,
neither interferes with cell growth nor indicates that the
association of the COG core proteins (COG1–COG4) has
been affected (19,20) which is consistent with data from
Caenorhabditis elegans where mutations in the COG subunits
of lobe A lead to a more severe phenotype than those occur-
ring in lobe B of the C. elegans complex (9). After identifi-
cation of a disease-causing mutation in subunit COG7 (12),
the COG6 deficiency described here is the second defect
with fatal outcome after a few weeks of life. Since both
subunits are the members of the COG complex lobe B, the
allocation of essential and non-essential subunits of the
human COG complex is therefore not compatible with the dis-
positions of subunits from the COG complexes of other
species. As also deficiencies of COG2 and COG3 of lobe A
have to be identified in patients, the concluding consideration
on the role of the different human COG complex subunits
remains to be solved.
MATERIALS AND METHODS
Cell lines and cell culture
Fibroblasts from the index patient and controls were main-
tained at 378C under 5% CO2 in Dulbecco’s modified
Eagle’s medium (DMEM, Invitrogen), which contained 10%
fetal calf serum (FCS; PAN Biotech GmbH), 50 IU/ml penicil-
lin and 50 mg/ml streptomycin. The ecotropic packaging cell
line FNX-Eco (ATCC) and the amphotropic packaging cell
line RetroPack PT67 (Clontech) cultured in DMEM contain-
ing 1× L-glutamine, 1× Pen/Strep and 10% fetal calf serum
(PAN Biotech GmbH), which was heat inactivated at 568C
for 30 min, at 378C under 5% CO2 unless otherwise stated.
Antibodies
For western blot analyses, the primary antibodies rabbit anti-
human ApoCIII (Biotrend, Cologne), the COG complex sub-
units COG1, COG4, COG5, COG6 and COG7 (D. Ungar),
human serum transferrin (DakoCytomation) and a-1-
antitrypsin (DakoCytomation) were used in dilutions of
1:1000 in PBST (0.1% Tween-20), respectively. Primary anti-
bodies mouse antihuman b-actin (Sigma-Aldrich) and mouse
antihuman GM130 (Sigma-Aldrich) were used in dilutions
of 1:10 000 in PBST and 1:200 in PBS, respectively. Second-
ary antibody goat anti-rabbit labelled with horseradish peroxi-
dase (Dianova) was used in a dilution of 1:10 000 in PBST.
Fluorochrome-conjugated secondary antibody goat anti-mouse
Alexa488 (Invitrogen) for the detection of human GM130 was
diluted 1:400 in PBST.
IEF and western blot analyses of serum transferrin
IEF and western blot analyses of serum transferrin were per-
formed as described previously (21).
IEF of a-1-antitrypsin
IEF of human a-1-antitrypsin was performed as described (22).
IEF of ApoCIII
IEF of ApoCIII was performed as described (23).
Neuraminidase treatment
Desialylation of glycopeptides of a control and the patient was
performed with two different neuraminidases, respectively.
2,3-neuraminidase (Takara) cuts sialic acid residues attached
to galactose residues in 2,3 orientation, whereas neuramini-
dase isolated from Vibrio cholerae (Roche) cuts 2,6-linked
sialic acid residues from N-acetylgalactosamine acids and
2,3-linked sialic acids residues from galactose residues. For
the assay 12.5 ml serum, 2.5 ml of 1 M NaAc (pH 5.0),
9.5 ml water and 1 ml (0.01 U) of the respective enzyme
were incubated at 378C for 4 h. One microlitre was used for
IEF of ApoCIII.

















0 0 0 0 0
5 95 10 14 93
10 100 81 86 94
15 100 98 93 100
Shown are percentage of cells with ER staining pattern at the respective time
points.
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Analysis of transferrin-linked N-glycans
Oligosaccharide moieties of a control and the patient’s serum
transferrin were isolated, purified and analysed by mass spec-
trometry on a Bruker Ultraflex TOF/TOF as described pre-
viously (24).
Histochemical staining with PNA
Control and patient-derived fibroblasts were stained with 2 mg/
ml biotinylated PNA (Vector Laboratories) in PBS/1% BSA
(Sigma-Aldrich) as described (25).
Analysis of UDP-[6-3H]galactose and CMP-[14C]NANA
import
The import of UDP-[6-3H]galactose (Perkin Elmer) and
CMP-[14C]NANA (Perkin Elmer) into Golgi-enriched vesicles
from control and patient’s fibroblasts was assessed as
described previously (26).
Analysis of UDP-galactose:N-acetylglucosamine
b-1,4-galactosyltransferase I activity and transfer of
CMP-[14C]NANA onto glycoproteins
The activity of the UDP-galactose:N-acetylglucosamine
b-1,4-galactosyltransferase I (b1,4GalTI) was determined as
described (24). Activity of the CMP-N-acetylneuraminate-
b-galactosamide-a-2,3-sialyltransferase (ST3GalTI) was
determined analogous to the b1,4GalTI measurement by fol-
lowing the transfer of 0.06 mCi CMP-[14C]NANA (Perkin
Elmer) onto acceptor protein asialofetuin type I
(Sigma-Aldrich).
Western blot analyses of the COG subunits
Patient and control fibroblasts were lysed in TBS/1% Triton
X-100/protease inhibitor mix (Serva) for 30 min on ice, fol-
lowed by sonification and vortexing. After centrifugation
(16 100 g, 48C for 20 min), 30 mg protein of the supernatant
was separated on a denaturing 10% SDS–polyacrylamide
gel and transferred onto a nitrocellulose membrane by
semi-dry western blotting. The membrane was blocked with
5% milk powder in PBST for 1 h at room temperature (RT)
and incubated with antibodies against COG1, COG4, COG5,
COG6 and COG7 as well as against b-actin in PBST overnight
at 48C. The membrane was washed three times with PBST for
20 min at RT and incubated with the secondary HRP-coupled
antibody for 1 h at RT. After washing, visualization was per-
formed by adding chemiluminescent reagent (Pierce).
Sequencing analyses
Total RNA was extracted from controls and patient-derived
fibroblasts using the RNAeasy kit (Qiagen). First-strand
cDNA was synthesized from 0.5 mg of total RNA with Omnis-
cript reverse transcriptase (Qiagen) and primer COG6-R1.
COG6 cDNA was amplified with primers COG6-F1 and
COG6-R1 with the HotStar-Taq-Polymerase kit (Qiagen)
with a preincubation at 958C for 15 min followed by 30
cycles with 1 min at 948C, 0.5 min at 558C and 4 min at
728C. The nested PCR with 35 cycles was carried out with
the primers COG6-F2 and COG6-R2. Reverse transcriptase–
PCR products were analysed on 1% agarose gels. PCR frag-
ments were prepared with the QIAquick PCR purification kit
(Qiagen) and subcloned into the pGEM-T-easy vector
(Promega). Genomic DNA was prepared from control and
patient-derived fibroblasts by the standard procedures (27).
In a first round of PCR, exon 2 of the COG6 gene was ampli-
fied from 100 ng template with primers COG6-Ex2-F1 and
COG6-Ex2-R1 using the Pfu-TurboTaq-Polymerase (Strata-
gene) with a preincubation at 958C for 1 min followed by 28
cycles with 1 min at 948C, 0.5 min at 558C and 1 min at
728C. Further amplification was carried out with nested
primers COG6-Ex2-F2 and COG6-Ex2-R2. PCR products
were analysed on a 1% agarose gel, extracted with the QIA-
quick PCR purification kit (Qiagen). Sequence analysis of
PCR products and plasmids was performed by dye-determined
cycle sequencing with primers COG6-F2, COG6-F3,
COG6-F4, COG6-F5 and COG6-R2 for COG6-cDNA and
with COG6-Ex2-F2 and COG6-R2 for exon 2 of COG6
gene on a Applied Biosystems model 373A automated sequen-
cer. Analyses of the COG5-, COG7- and COG8-cDNAs from
the patient and controls were performed accordingly to the
protocol for COG6 mentioned above. Primers for PCR ampli-
fications and sequencing are listed in Table 2.
Northern blotting
Northern blotting was carried out for COG6 and b-actin by
following the standard procedures (27) with 5 mg of total
RNA extracted from controls and patient-derived fibroblasts
using the RNAeasy kit (Qiagen). RNA was transferred onto
a nylon membrane (Amersham HybondTM-N+, GE Health-
care). Labelling of the COG6-specific probe (10 ng), amplified
with primers COG6-F4 and COG6-R2 or the b-actin probe
(10 ng; Roche), was carried out with the ‘random prime label-
ling system’ (GE Healthcare) after addition of [a-32P]dCTP
(3000 Ci/mmol; Perkin Elmer) by adhering the manufacturer’s
guidelines. Hybridization in Amersham Rapid-hyb
TM
Buffer
(GE Healthcare) was accomplished at 708C for 2 h. Washing
of the blot was performed in 2× SSC [0.3 M NaCl, 0.03 M Na3-
citrate with 0.1% (w/v) SDS at 748C for 20 min and 2×
15 min in 0.2× SSC with 0.1% (w/v) SDS at 658C], followed
by exposure to an autoradiography film.
Retroviral complementation
Ecotropic FNX-Eco cells (5 × 105) were seeded onto dishes
(60-mm diameter) 1 day before transfection. Transient trans-
fection by FuGENE6 reagent was performed according to
the manufacturer’s protocol (Roche), with 1 mg of LNCX2
vector (mock), and LNCX2 with the wild-type
COG6-cDNA. Further procedures were performed as
described elsewhere (28). The supernatant with the amphotro-
pic retroviral particles was used to transfect patient and control
fibroblasts. After infection of fibroblasts, the medium was
replaced by DMEM, containing 10% heat-inactivated FCS
with 225 mg/ml G418 (Gibco BRL). Selection was carried
out for 10 days.
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Gel filtration chromatography
Control and patient-derived fibroblasts were lysed in PBS
complemented with 1× protease inhibitor mix (Serva)
and 0.75% 3-[(3-cholamido-propyl)dimethylammonium]-1-
propanesulfonate by passing 20 times through a dounce hom-
ogenizer. After centrifugation at 100 000g and 48C for 30 min,
the supernatant was removed and put on ice. The protein con-
centration of the supernatant was adjusted to 8 mg protein in
400 ml PBS and fractionated over a Superose 6 10/300 GL
gel filtration column (GE Healthcare) by FPLC in PBS with
a flowrate of 0.25 ml/min for 96 min. For precipitation, each
fraction was filled with four volumes of ice-cold acetone and
incubated overnight at 2208C. Proteins of each fraction
were pelleted by centrifugation at 13000 rpm and 48C for
15 min, washed with 50% acetone/H2O and analysed by
western blot with an antibody against COG4. Marker proteins
thyroglobulin, ferritin and aldolase were purchased from GE
Healthcare (Gel Filtration Calibration Kit).
BFA assay
Cells from a control and our patient were grown on glass cover
slips for 16 h. After removal of the medium, pre-heated
DMEM containing 10% FCS/50 IU/ml penicillin and 50 mg/
ml streptomycin/2.5 mg/ml BFA was added to the plate, fol-
lowed by incubation for 0–15 min at 378C and 5% CO2.
Incubation was terminated by putting the cells on ice, rinsed
twice with ice-cold PBS and fixed with 3% paraformaldehyde
for 20 min. After washing the cover slips twice with PBS, free
aldehyde groups were blocked with 50 mM NH4Cl in PBS for
10 min and the cells were permeabilized with 0.5% Triton
X-100. Subsequently, the cells were incubated with antibodies
against GM130 for 1 h at 378C, washed with PBS, and then
incubated with 10% goat serum in PBS for 20 min. Primary
antibodies were detected by secondary antibodies conjugated
to the fluorochromes Alexa488. After washing with PBS, the
cells were mounted in Vectashield mounting medium with
DAPI and analysed using a spinning disk confocal laser micro-
scope (ERS6; Perkin Elmer). Quantification of the ER staining
pattern was performed in control and patient-derived fibro-
blasts by analysing 300 cells each after BFA treatment at
different time points.
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